Clinical Trials
83
Active:81
Completed:1
Trial Phases
2 Phases
Phase 1:34
Phase 2:1
Drug Approvals
58
CIMA_AEMPS:20
SFDA:16
NMPA:14
+1 more agencies
Drug Approvals
Lanreotide acetate sustained-release injection (a pre-filled syringe)
- Product Name
- 醋酸兰瑞肽缓释注射液(预充式)
- Approval Number
- 国药准字HJ20190059
- Approval Date
- May 22, 2024
NMPA
Lanreotide acetate sustained-release injection (a pre-filled syringe)
- Product Name
- 醋酸兰瑞肽缓释注射液(预充式)
- Approval Number
- 国药准字HJ20190057
- Approval Date
- May 22, 2024
NMPA
Lanreotide acetate sustained-release injection (a pre-filled syringe)
- Product Name
- 醋酸兰瑞肽缓释注射液(预充式)
- Approval Number
- 国药准字HJ20190058
- Approval Date
- May 22, 2024
NMPA
Triptorelin Pamoate for Injection
- Product Name
- 注射用双羟萘酸曲普瑞林
- Approval Number
- 国药准字HJ20230075
- Approval Date
- Jun 21, 2023
NMPA
Triptorelin Acetate for Injection
- Product Name
- 达菲林
- Approval Number
- 国药准字HJ20140298
- Approval Date
- Jun 7, 2023
NMPA
Triptorelin pamoate for injection
- Product Name
- 注射用双羟萘酸曲普瑞林
- Approval Number
- 国药准字HJ20130842
- Approval Date
- May 16, 2023
NMPA
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (36 trials with phase data)• Click on a phase to view related trials
Phase 1
34 (94.4%)Phase 2
1 (2.8%)phase_2_3
1 (2.8%)No trials found
News
Radius Pharmaceuticals Secures Patent Victory for TYMLOS Osteoporosis Treatment Through 2038
The U.S. District Court for the District of Massachusetts ruled in favor of Radius Pharmaceuticals and Ipsen in a patent infringement case against Orbicular Pharmaceutical Technologies for their proposed generic TYMLOS product.
NALIRIFOX Shows Numerically Improved Overall Survival Compared to FOLFIRINOX in Metastatic PDAC
A real-world study indicated that first-line NALIRIFOX had a numerically higher median overall survival (OS) of 11.1 months compared to FOLFIRINOX's 9.1 months in mPDAC patients.